- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03588364
The Role of Osteopathic Manipulation in the the Management of Post-traumatic Migraine (OMT/mTBI)
June 10, 2019 updated by: Hollis King, University of California, San Diego
This study evaluates the use of osteopathic manipulation (manual medicine) for migraine headache following traumatic head injury.
Headache is an important and very common somatic complaint among people with traumatic brain injury and an important cause of disability in the United States.
Over 15-percent of soldiers deployed to Iraq sustained concussion.
A majority of these patients suffer from headaches.
Many of these are classified as migraine headache that do not respond to medications.
Osteopathic manipulation is practiced by physicians in the United States and has been shown to be beneficial in some migraine patients.
However, its use in the management of persistent post-traumatic headaches has not been explored.
The investigators will use a randomized cross-over design to evaluate post-traumatic migraine patients' response to osteopathic manipulation.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
This is a 30-week prospective, randomized delayed treatment control group design in which 20 participants from the community will be randomized 1:1 into (a) an immediate treatment group that will receive 12 weeks of osteopathic manipulation (OMT) treatment plus standard of care right away or (b) delayed treatment group that will receive 12 weeks of OMT plus standard of care after a 6-week waiting period.
The delayed treatment group initially serves as a control condition but then receives the experimental treatment.
The investigators selected this control condition to improve our statistical power in this small pilot study.
As noted, all participants will continue to receive standard of care throughout the study as a washout is not feasible with osteopathic manipulation and removing standard of care could exacerbate the participant's symptoms.
Participants in both arms will be followed for another 12 weeks after the 12 weeks of OMT, resulting in 24 weeks of study participation for the immediate treatment group and 30 weeks of study participation for the delayed treatment group, with participants in both arms answering a series of questionnaires to evaluate migraine frequency and impact, treatment efficacy, side effects, adherence t standard of care and depressive symptoms every 6 weeks throughout their study participation.
Participant encounters will consist of screening, psychometric and functional scale administration at every 6 weeks for a total of 24-30 weeks, as well as 12 weeks of OMT treatments for participants in both study arms.
Study participants will likely come from UCSD internal referrals.
Study Type
Interventional
Enrollment (Actual)
11
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
California
-
La Jolla, California, United States, 92093
- University of California, San Diego
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- History of TBI, concussion, post-concussive syndrome
- Headache frequency >/equal 4 per month
- Post-traumatic headache, migraine type
- MIDAS Grade I-IV
- Headaches continue to occur 3 months to 1 year after the injury
- No history of uncontrolled migraine prior to head injury
Exclusion Criteria:
- Headache medication change (Tricyclic antidepressant, antiepileptic medication, propranolol, verapamil, duloxetine, butterbur, Botox) within 30 days
- Non-pharmacologic headache management change (reduction in caffeine intake, reduction in alcohol intake, sleep hygiene, exercise) within 30 days
- Less than 3 months from injury
- History of uncontrolled migraine prior to TBI
- Currently taking oral anti-coagulants
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: CROSSOVER
- Masking: TRIPLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
EXPERIMENTAL: Osteopathic Manipulation
Twelve weekly sessions using the techniques of osteopathy in the cranial field.
|
Osteopathic manipulation involves a number of different manual techniques.
These include muscle inhibition; myofascial release; muscle energy stretch; counterstrain; facilitated positional release ; osteopathy in the cranial field ; balanced ligamentous tension/ligamentous articular strain; one or all of these techniques may be used.
Participants will be positioned on an exam table supine, seated, lateral decubitus, prone, or in their position of greatest comfort for the procedure.
|
|
NO_INTERVENTION: Waitlist Control
Six-week waiting period.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Headache Frequency Log
Time Frame: 6 weeks
|
Participants will complete a form indicating the frequency, location, duration, characteristics, and associated features of their headache.
|
6 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Migraine Disability Assessment Score (MIDAS)
Time Frame: 6 weeks
|
Scale measures migraine disability by asking participants to indicate number of various events missed (or completed with reduced productivity) over the past three months; as well as average pain associated with headaches in the past 3 months.
|
6 weeks
|
|
Center for Epidemiological Studies-Depression (CES-D)
Time Frame: 6 weeks
|
20-item measure that asks respondents to rate how often over the past week they experienced symptoms associated with depression, such as restless sleep, poor appetite, and feeling lonely.
Response options range from 0 to 3 for each item (0 = Rarely or None of the Time, 1 = Some or Little of the Time, 2 = Moderately or Much of the time, 3 = Most or Almost All the Time).
Scores range from 0 to 60, with high scores indicating greater depressive symptoms.
|
6 weeks
|
|
36-Item Short Form Survey Instrument (MOS-SF-36)
Time Frame: 6 weeks
|
36-item, patient-reported survey of health-related quality of life.
Each of the eight scales is transformed into a 0-100 scale.
The 8 scales include: vitality, physical functioning, bodily pain, general health perceptions, physical role functioning, emotional role functioning, social role functioning, and mental health.
|
6 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
September 15, 2016
Primary Completion (ACTUAL)
December 1, 2018
Study Completion (ACTUAL)
June 1, 2019
Study Registration Dates
First Submitted
July 4, 2018
First Submitted That Met QC Criteria
July 4, 2018
First Posted (ACTUAL)
July 17, 2018
Study Record Updates
Last Update Posted (ACTUAL)
June 12, 2019
Last Update Submitted That Met QC Criteria
June 10, 2019
Last Verified
June 1, 2019
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- OMT/mTBI
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.